STAT3 and B-cell chronic lymphocytic leukemia: Our data provide a novel mechanism for T-cell dysfunction in CLL, involving the CXCL12–CXCR4–STAT3 signaling pathway and CLL B10 function, and provide additional targets of lenalidomide that can account for its therapeutic immunomodulatory effect in CLL.